GB1381426A - Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents - Google Patents
Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agentsInfo
- Publication number
- GB1381426A GB1381426A GB1727573A GB1727573A GB1381426A GB 1381426 A GB1381426 A GB 1381426A GB 1727573 A GB1727573 A GB 1727573A GB 1727573 A GB1727573 A GB 1727573A GB 1381426 A GB1381426 A GB 1381426A
- Authority
- GB
- United Kingdom
- Prior art keywords
- acid ester
- polyoxyethylene
- surface active
- sulphuric acid
- aliphatic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1381426 Pharmaceutical compositions CHUGAI SEIYAKU KK 10 April 1973 17275/73 Heading A5B Pharmaceutical compositions useful in the treatment of arteriosclerosis and having increased absorption of an oligosaccharide sulphuric acid ester through the wall of the digestive tract comprise at least one oligosaccharide sulphuric acid ester having an overage degree of polymerization of from 2 to 20, and at least one nonionic surface active agent in an amount of from 1 to 20% by weight based on the weight of the oligosaccharide sulphuric acid ester. The surface active agent may be a polyoxyethylene C 5-20 alcohol ether, a polyoxyethylene aliphatic acid ester, a sorbitan aliphatic acid ester, a polyoxyethylene sorbitan aliphatic acid ester, a polyoxyethylene sorbital aliphatic acid ester, a polyoxyethylene hydrogenated castor oil derivative, glyceryl monoaliphatic acid ester or a sucrose aliphatic acid ester. The compositions may be administered orally in the form of tablets, pills, granules, powders, capsules or aqueous preparations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1727573A GB1381426A (en) | 1973-04-10 | 1973-04-10 | Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1727573A GB1381426A (en) | 1973-04-10 | 1973-04-10 | Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1381426A true GB1381426A (en) | 1975-01-22 |
Family
ID=10092354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1727573A Expired GB1381426A (en) | 1973-04-10 | 1973-04-10 | Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB1381426A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0056379A1 (en) * | 1980-07-02 | 1982-07-28 | Commw Scient Ind Res Org | Controlled release compositions for administration of therapeutic agents to ruminants. |
EP0130550A2 (en) * | 1983-06-29 | 1985-01-09 | Intermedicat GmbH | Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat |
EP0147526A1 (en) * | 1983-08-27 | 1985-07-10 | BASF Aktiengesellschaft | Method of enhancing the enteric resorption of heparin and a heparin preparation so obtained |
EP0230023A2 (en) * | 1985-12-24 | 1987-07-29 | Marion Merrell Dow Inc. | Pharmaceutical compositions for the enhancement of wound healing |
EP0479093A1 (en) * | 1990-10-03 | 1992-04-08 | F. Hoffmann-La Roche Ag | Oligosaccharide derivatives and their use as medicaments |
EP1014996A1 (en) * | 1997-08-28 | 2000-07-05 | The University Of Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
-
1973
- 1973-04-10 GB GB1727573A patent/GB1381426A/en not_active Expired
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0056379A1 (en) * | 1980-07-02 | 1982-07-28 | Commw Scient Ind Res Org | Controlled release compositions for administration of therapeutic agents to ruminants. |
EP0056379A4 (en) * | 1980-07-02 | 1983-10-07 | Commw Scient Ind Res Org | Controlled release compositions for administration of therapeutic agents to ruminants. |
EP0130550A2 (en) * | 1983-06-29 | 1985-01-09 | Intermedicat GmbH | Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat |
EP0130550A3 (en) * | 1983-06-29 | 1986-12-30 | Intermedicat GmbH | Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat |
EP0147526A1 (en) * | 1983-08-27 | 1985-07-10 | BASF Aktiengesellschaft | Method of enhancing the enteric resorption of heparin and a heparin preparation so obtained |
US4656161A (en) * | 1983-08-27 | 1987-04-07 | Basf Aktiengesellschaft | Increasing the enteral absorbability of heparin or heparinoids |
EP0230023A2 (en) * | 1985-12-24 | 1987-07-29 | Marion Merrell Dow Inc. | Pharmaceutical compositions for the enhancement of wound healing |
EP0230023A3 (en) * | 1985-12-24 | 1988-11-17 | Marion Laboratories Inc | Pharmaceutical compositions for the enhancement of wound healing |
EP0479093A1 (en) * | 1990-10-03 | 1992-04-08 | F. Hoffmann-La Roche Ag | Oligosaccharide derivatives and their use as medicaments |
US5298616A (en) * | 1990-10-03 | 1994-03-29 | Hoffmann-La Roche Inc. | Sulfated O-polysaccharide-trehaloses |
EP1014996A1 (en) * | 1997-08-28 | 2000-07-05 | The University Of Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
EP1014996A4 (en) * | 1997-08-28 | 2000-10-11 | Univ Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES424533A1 (en) | Slow release pharmaceutical compositions | |
US5185159A (en) | Pharmaceutical composition based on valproic acid and a process for preparing it | |
KR890009376A (en) | Spray dried ibuprofen | |
EP0165352A3 (en) | Clear micellized solutions of fat soluble essential nutrients | |
DE3420283A1 (en) | NIFEDIPINE DRY PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF | |
GR3017411T3 (en) | Production process of microspheres. | |
FR2698788B1 (en) | Effervescent pharmaceutical composition containing ibuprofen and process for its preparation. | |
ES8100883A1 (en) | Transdermal medication system for isosorbide dinitrate | |
IE810036L (en) | Sustained release compositions | |
GB1381426A (en) | Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents | |
IE821796L (en) | Waterless thixotropic composition | |
KR940011014A (en) | Stabilized Superoxide Dismutase (SOD) Compositions | |
ZA837412B (en) | Compressed products with retarded release of active substance | |
US3777020A (en) | Psoriasis treatment with mycophenolic acid | |
IE801402L (en) | Gastric acid neutralizing agents | |
Windsor et al. | Effect of tetracycline on leucocyte ascorbic acid levels | |
DE2963545D1 (en) | Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation | |
US4975423A (en) | Inhibition of tumor development | |
US4391809A (en) | Methods for treating psoriasis | |
DD249186A1 (en) | METHOD OF MANUFACTURING A NEW GLIBENCLAMID MEDICAMENT WITH HIGHER BIODEGRADABILITY | |
JPS5731614A (en) | Lipid improver | |
DE1543733C3 (en) | Aluminum bis-alpha- (p-chlorophenoxy) isobutyrate and brightening agents containing this compound as an active ingredient | |
JPS57158719A (en) | Rectal administration pharmaceutical | |
JPS5513241A (en) | Remedy for glaucoma | |
DE2643303A1 (en) | HYPOGLYKAEMICALLY ACTIVE DRUG |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CSNS | Application of which complete specification have been accepted and published, but patent is not sealed |